NRx Pharmaceuticals Secures $22.3M in Public Offering, Including Full Underwriter Option Exercise
NRXP has more than doubled off its 52-week low of $1.62.
Summary
NRx Pharmaceuticals has closed its public offering, raising $22.3 million in gross proceeds. This includes the full exercise of the underwriters' option, which increased the capital raised from the initially priced $20 million. This financing is crucial for the company, which has reported 'going concern' warnings in recent SEC filings (10-K and 10-Q), indicating significant liquidity needs. The capital will be used for working capital and general corporate purposes, supporting its ongoing clinical-stage biopharmaceutical development.
At the time of this announcement, NRXP was trading at $4.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.7M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.